WO2009082624A3 - Antagonists of il-17a, il-17f, and il-23 and methods of using the same - Google Patents

Antagonists of il-17a, il-17f, and il-23 and methods of using the same Download PDF

Info

Publication number
WO2009082624A3
WO2009082624A3 PCT/US2008/086292 US2008086292W WO2009082624A3 WO 2009082624 A3 WO2009082624 A3 WO 2009082624A3 US 2008086292 W US2008086292 W US 2008086292W WO 2009082624 A3 WO2009082624 A3 WO 2009082624A3
Authority
WO
WIPO (PCT)
Prior art keywords
antagonists
methods
same
antibodies
superior
Prior art date
Application number
PCT/US2008/086292
Other languages
French (fr)
Other versions
WO2009082624A2 (en
Inventor
Katherine E. Lewis
Ty M. Brender
Eugene C. Yi
Penny J. Thompson
Brenda L. Stevens
George Robert Mabry Iii
Scott R. Presnell
Margaret D. Moore
Patricia I. Guerra-Lewis
Original Assignee
Zymogenetics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics, Inc. filed Critical Zymogenetics, Inc.
Publication of WO2009082624A2 publication Critical patent/WO2009082624A2/en
Publication of WO2009082624A3 publication Critical patent/WO2009082624A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17, IL-23p19 or both IL-17 and IL-23p19. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease. In particular, antibodies and antibody fragments that have superior neutralizing potency for the IL-17A/F heterodimer, and bispecific molecules that combine this superior anti-IL-17A antibody with anti-IL-23A antibodies are disclosed.
PCT/US2008/086292 2007-12-10 2008-12-10 Antagonists of il-17a, il-17f, and il-23 and methods of using the same WO2009082624A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US1276707P 2007-12-10 2007-12-10
US61/012,767 2007-12-10
US1951808P 2008-01-07 2008-01-07
US61/019,518 2008-01-07
US3902208P 2008-03-24 2008-03-24
US61/039,022 2008-03-24

Publications (2)

Publication Number Publication Date
WO2009082624A2 WO2009082624A2 (en) 2009-07-02
WO2009082624A3 true WO2009082624A3 (en) 2009-10-29

Family

ID=40679588

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/086292 WO2009082624A2 (en) 2007-12-10 2008-12-10 Antagonists of il-17a, il-17f, and il-23 and methods of using the same

Country Status (1)

Country Link
WO (1) WO2009082624A2 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2784084B2 (en) 2003-07-08 2023-10-04 Novartis Pharma AG Antagonist antibodies to IL-17A/F heterologous polypeptides
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
CA2655372A1 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
ES2378407T3 (en) 2006-09-01 2012-04-12 Therapeutic Human Polyclonals, Inc. Increased expression of human or humanized immunoglobulin in non-human transgenic animals
PL2059534T3 (en) 2007-02-23 2012-09-28 Merck Sharp & Dohme Engineered anti-il-23p19 antibodies
EP2064242A1 (en) 2007-02-23 2009-06-03 Schering Corporation Engineered anti-il-23p19 antibodies
WO2010128407A2 (en) * 2009-05-05 2010-11-11 Novimmune S.A. Anti-il-17f antibodies and methods of use thereof
WO2011032119A1 (en) 2009-09-14 2011-03-17 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses
JO3244B1 (en) 2009-10-26 2018-03-08 Amgen Inc Human il-23 antigen binding proteins
MX2012005086A (en) 2009-10-30 2012-09-28 Janssen Biotech Inc Il-17a antagonists.
WO2011119948A1 (en) * 2010-03-26 2011-09-29 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
AU2011282476B2 (en) 2010-07-20 2015-08-20 Cephalon Australia Pty Ltd Anti-IL-23 heterodimer specific antibodies
EA030436B1 (en) 2010-11-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх ANTI-IL-23p19 ANTIBODIES OR ANTIGEN-BINDING FRAGMENTS THEREOF, USE THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING THESE ANTIBODIES, METHOD FOR PRODUCING SAME, ISOLATED POLYNUCLEOTIDES, EXPRESSION VECTORS AND CELLS FOR PRODUCING ANTIBODIES
WO2012103165A2 (en) 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
UA117218C2 (en) 2011-05-05 2018-07-10 Мерк Патент Гмбх Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
RU2652886C2 (en) * 2011-10-20 2018-05-03 ИЭсБиЭйТЕК-Э НОВАРТИС КОМПАНИ ЭлЭлСи Stable multiple antigen-binding antibodies
US20130165638A1 (en) * 2011-12-27 2013-06-27 Development Center For Biotechnology Light chain-bridged bispecific antibody
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
EP3326649B1 (en) 2012-05-03 2022-02-09 Boehringer Ingelheim International GmbH Anti-il-23p19 antibodies
CN104884473B (en) 2012-05-22 2019-12-03 百时美施贵宝公司 IL-17A/F IL-23 bispecific antibody and its application
WO2014004436A2 (en) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Crystalline anti-human il-23 antibodies
DK3381943T3 (en) 2012-07-25 2022-05-16 Celldex Therapeutics Inc ANTI-KIT ANTIBODIES AND USES THEREOF
AR094877A1 (en) * 2013-03-08 2015-09-02 Lilly Co Eli ANTIBODIES THAT JOIN IL-23
EA201591581A1 (en) 2013-03-15 2016-01-29 Амген Инк. METHODS OF TREATING PSORIASIS WITH ANTI-IL-23 ANTIBODIES
EP2968486A1 (en) 2013-03-15 2016-01-20 Amgen Inc. Methods for treating crohn's disease using an anti-il23 antibody
CA2929662C (en) * 2013-11-18 2023-05-02 Shanghai Hengrui Pharmaceutical Co., Ltd. Il-17a binding agent and uses thereof
US10239943B2 (en) 2014-05-23 2019-03-26 Celldex Therapeutics, Inc. Treatment of eosinophil or mast cell related disorders
US20170291939A1 (en) * 2014-06-25 2017-10-12 Novartis Ag Antibodies specific for il-17a fused to hyaluronan binding peptide tags
EP3708679A1 (en) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
TWI711629B (en) 2014-09-03 2020-12-01 德商包林格因蓋爾漢國際股份有限公司 Compound targeting il-23a and tnf-alpha and uses thereof
CA2998349A1 (en) 2015-09-17 2017-03-23 Amgen Inc. Prediction of clinical response to il23-antagonists using il23 pathway biomarkers
JP7085992B2 (en) * 2015-10-29 2022-06-17 エフ．ホフマン－ラ ロシュ アーゲー Transgenic rabbits with a common light chain
US20180291093A1 (en) * 2015-10-30 2018-10-11 Eli Lilly And Company Anti-cgrp/anti-il-23 bispecific antibodies and uses thereof
CN108472367A (en) 2015-12-22 2018-08-31 美国安进公司 The CCL20 of predictive factor as the clinical response to IL23 antagonists
CR20180529A (en) * 2016-04-04 2019-03-21 Bioverativ Usa Inc ANTI-FACTOR ANTIBODIES BB OF THE COMPLEMENT AND USES OF THESE CROSSED REFERENCES
US11192944B2 (en) 2017-10-11 2021-12-07 Bioverativ Usa Inc. Methods of inducing complement activity
WO2019094626A1 (en) * 2017-11-08 2019-05-16 Fred Hutchinson Cancer Research Center Bispecific antibody compositions and related methods for improved pretargeted radioimunotherapies
SG11202100185VA (en) 2018-07-13 2021-02-25 Astrazeneca Collaboration Ventures Llc Treating ulcerative colitis with brazikumab
CN112513078B (en) * 2018-07-31 2022-11-18 沈为群 anti-IL-17A antibodies and uses thereof
CN114127108A (en) * 2019-07-30 2022-03-01 江苏恒瑞医药股份有限公司 Methods of treating autoimmune diseases with IL-17 antagonists
WO2021126435A1 (en) 2019-12-20 2021-06-24 Novarock Biotherapeutics, Ltd. Anti-interleukin-23 p19 antibodies and methods of use thereof
KR20210095781A (en) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 A multi-specific antibody comprising a fusion construct consisting of a Fab and a bioactive effector moiety
TW202140543A (en) 2020-04-20 2021-11-01 美商健臻公司 Humanized anti-complement factor bb antibodies and uses thereof
JP2023525234A (en) * 2020-04-30 2023-06-15 ヤンセン ファーマシューティカ エヌ．ベー． Methods of identifying modulators of the IL-17 pathway
CN113769082A (en) * 2020-06-10 2021-12-10 上海君实生物医药科技股份有限公司 anti-IL-17A antibody pharmaceutical composition and application thereof

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071517A2 (en) * 2003-02-06 2004-08-26 Schering Corporation Uses of il-23 related reagents
WO2004106377A1 (en) * 2003-05-30 2004-12-09 Celltech R & D Limited Methods for producing antibodies
WO2005051422A1 (en) * 2003-11-21 2005-06-09 Celltech R & D Limited Method for the treatment of multiple sclerosis by inhibiting il-17 activity
US20050244874A1 (en) * 2004-05-03 2005-11-03 Schering Corporation Use of IL-17 expression to predict skin inflammation; methods of treatment
WO2006013107A1 (en) * 2004-08-05 2006-02-09 Novartis Ag Il-17 antagonistic antibodies
WO2006054059A1 (en) * 2004-11-19 2006-05-26 Ucb Pharma S.A. Neutralising antibody molecules having specificity for human il-17
WO2007024846A2 (en) * 2005-08-25 2007-03-01 Eli Lilly And Company Anit-il-23 antibiodies
WO2007027761A2 (en) * 2005-09-01 2007-03-08 Schering Corporation Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
WO2007070750A1 (en) * 2005-12-13 2007-06-21 Eli Lilly And Company Anti-il-17 antibodies
US20070212362A1 (en) * 1998-05-15 2007-09-13 Filvaroff Ellen H Use of il-17 antibody for the treatment of cartilage damaged by osteoarthritis
WO2007106769A2 (en) * 2006-03-10 2007-09-20 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
WO2007147019A2 (en) * 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070212362A1 (en) * 1998-05-15 2007-09-13 Filvaroff Ellen H Use of il-17 antibody for the treatment of cartilage damaged by osteoarthritis
WO2004071517A2 (en) * 2003-02-06 2004-08-26 Schering Corporation Uses of il-23 related reagents
WO2004106377A1 (en) * 2003-05-30 2004-12-09 Celltech R & D Limited Methods for producing antibodies
WO2005051422A1 (en) * 2003-11-21 2005-06-09 Celltech R & D Limited Method for the treatment of multiple sclerosis by inhibiting il-17 activity
US20050244874A1 (en) * 2004-05-03 2005-11-03 Schering Corporation Use of IL-17 expression to predict skin inflammation; methods of treatment
WO2006013107A1 (en) * 2004-08-05 2006-02-09 Novartis Ag Il-17 antagonistic antibodies
WO2006054059A1 (en) * 2004-11-19 2006-05-26 Ucb Pharma S.A. Neutralising antibody molecules having specificity for human il-17
WO2007024846A2 (en) * 2005-08-25 2007-03-01 Eli Lilly And Company Anit-il-23 antibiodies
WO2007027761A2 (en) * 2005-09-01 2007-03-08 Schering Corporation Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
WO2007070750A1 (en) * 2005-12-13 2007-06-21 Eli Lilly And Company Anti-il-17 antibodies
WO2007106769A2 (en) * 2006-03-10 2007-09-20 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
WO2007147019A2 (en) * 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHAN JASON R ET AL: "IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis", JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, JP, vol. 203, no. 12, 27 November 2006 (2006-11-27), pages 2577 - 2587, XP002489063, ISSN: 0022-1007 *
ZHANG ET AL: "After interleukin-12p40, are interleukin-23 and interleukin-17 the next therapeutic targets for inflammatory bowel disease?", INTERNATIONAL IMMUNOPHARMACOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 7, no. 4, 21 February 2007 (2007-02-21), pages 409 - 416, XP005900655, ISSN: 1567-5769 *

Also Published As

Publication number Publication date
WO2009082624A2 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
WO2009082624A3 (en) Antagonists of il-17a, il-17f, and il-23 and methods of using the same
WO2008134659A3 (en) Antagonists to il-17a, il-17f, and il-23p19 and methods of use
WO2007106769A3 (en) Antibodies that bind both il-17a and il-17f and methods of using the same
WO2008133684A8 (en) Antibodies that bind both il-17a and il-17f and methods of using the same
WO2005123778A3 (en) Soluble zcytor14, anti-zcytor14 antibodies and binding partners and methods of using in inflammation
WO2008039553A8 (en) Soluble il-17rcx4 and methods of using in inflammation
WO2004085475A3 (en) Anti-il-20 antibodies and binding partners and methods of using in inflammation
WO2009136286A3 (en) Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
WO2007126439A3 (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
HK1110333A1 (en) Anti-il-22ra antibodies and binding partners and methods of using in inflammation
WO2006086396A3 (en) Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
WO2007147019A3 (en) Il-17 and il-23 antagonists and methods of using the same
WO2010128407A3 (en) Anti-il-17f antibodies and methods of use thereof
UA95478C2 (en) Humanized c-kit antibody
HK1112927A1 (en) Il-17a and il-17f antagonists and methods of using the same il-17a
WO2008019061A3 (en) Anti-il-6 monoclonal antibodies and uses thereof
WO2011053763A3 (en) Il-17a antagonists
WO2005080429A3 (en) Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies
WO2005052001A3 (en) Anti-il-20 receptor antibodies and binding partners and methods of using in inflammation
WO2007100643A3 (en) Methods of using antibodies against human il-22
WO2006003388A8 (en) Compositions and methods for treating inflammatory disorders
CL2007003479A1 (en) Human anti-cd22 monoclonal antibody or an antigen-binding fragment thereof; nucleic acid, vector, host cell; Preparation method; composition; immunoconjugate; and its use to inhibit the growth of a tumor or treat an inflammatory or autoimmune disorder in a subject.
WO2011079308A3 (en) Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
WO2015191783A3 (en) Biomarkers for inflammatory disease and methods of using same
WO2008049070A3 (en) Il-17c antagonists and methods of using the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08865241

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08865241

Country of ref document: EP

Kind code of ref document: A2